{"id":"https://openalex.org/W3134477587","doi":"https://doi.org/10.1136/jitc-2020-002068","title":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","display_name":"Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer","publication_year":2021,"publication_date":"2021-03-01","ids":{"openalex":"https://openalex.org/W3134477587","doi":"https://doi.org/10.1136/jitc-2020-002068","mag":"3134477587","pmid":"https://pubmed.ncbi.nlm.nih.gov/33688022","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7944986"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2020-002068","doi":"https://doi.org/10.1136/jitc-2020-002068","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-002068","pdf_url":"https://jitc.bmj.com/content/jitc/9/3/e002068.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/9/3/e002068.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049680516","display_name":"Davide Melisi","orcid":"https://orcid.org/0000-0002-4031-7585","observed_orcids":["https://orcid.org/0000-0002-4031-7585"]},"institutions":[{"id":"https://openalex.org/I119439378","display_name":"University of Verona","ror":"https://ror.org/039bp8j42","country_code":"IT","type":"education","lineage":["https://openalex.org/I119439378"]}],"countries":["IT"],"is_corresponding":true,"raw_author_name":"Davide Melisi","raw_affiliation_strings":["Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Universit\u00e0 degli Studi di Verona, Verona, Italy"],"raw_orcid":"https://orcid.org/0000-0002-4031-7585","affiliations":[{"raw_affiliation_string":"Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Universit\u00e0 degli Studi di Verona, Verona, Italy","institution_ids":["https://openalex.org/I119439378"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059766169","display_name":"Do\u2010Youn Oh","orcid":"https://orcid.org/0000-0003-1663-9901","observed_orcids":["https://orcid.org/0000-0003-1663-9901"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Do-Youn Oh","raw_affiliation_strings":["Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086593040","display_name":"Antoine Hollebecque","orcid":"https://orcid.org/0000-0003-2869-7551","observed_orcids":["https://orcid.org/0000-0003-2869-7551"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Antoine Hollebecque","raw_affiliation_strings":["Institut Gustave Roussy, Villejuif, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave Roussy, Villejuif, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053069942","display_name":"Emiliano Calvo","orcid":"https://orcid.org/0000-0003-4921-829X","observed_orcids":["https://orcid.org/0000-0003-4921-829X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emiliano Calvo","raw_affiliation_strings":["START Madrid\u2013CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Madrid\u2013CIOCC, Centro Integral Oncol\u00f3gico Clara Campal, Madrid, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027467209","display_name":"Anna M. Varghese","orcid":"https://orcid.org/0000-0001-5426-0885","observed_orcids":["https://orcid.org/0000-0001-5426-0885"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna Varghese","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, New York, USA","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070523850","display_name":"Erkut Hasan Borazanci","orcid":"https://orcid.org/0000-0001-5136-5462","observed_orcids":["https://orcid.org/0000-0001-5136-5462"]},"institutions":[{"id":"https://openalex.org/I1284308235","display_name":"Translational Genomics Research Institute","ror":"https://ror.org/02hfpnk21","country_code":"US","type":"facility","lineage":["https://openalex.org/I1284308235"]},{"id":"https://openalex.org/I4210130412","display_name":"HonorHealth","ror":"https://ror.org/03szbwj17","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210130412"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erkut Borazanci","raw_affiliation_strings":["HonorHealth Research Institute, Scottsdale, Arizona, USA","TGen, Phoenix, Arizona, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HonorHealth Research Institute, Scottsdale, Arizona, USA","institution_ids":["https://openalex.org/I4210130412"]},{"raw_affiliation_string":"TGen, Phoenix, Arizona, USA","institution_ids":["https://openalex.org/I1284308235"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082191671","display_name":"Teresa Mercade Macarulla","orcid":"https://orcid.org/0000-0002-5856-4082","observed_orcids":["https://orcid.org/0000-0002-5856-4082","https://orcid.org/0000-0002-1881-362X"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Teresa Macarulla","raw_affiliation_strings":["Vall d\u2019Hebron University Hospital and Vall d\u2019Hebron Institute of Oncology (VHIO), Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron University Hospital and Vall d\u2019Hebron Institute of Oncology (VHIO), Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073612690","display_name":"Valeria Merz","orcid":"https://orcid.org/0000-0002-2120-1923","observed_orcids":["https://orcid.org/0000-0002-2120-1923"]},"institutions":[{"id":"https://openalex.org/I119439378","display_name":"University of Verona","ror":"https://ror.org/039bp8j42","country_code":"IT","type":"education","lineage":["https://openalex.org/I119439378"]},{"id":"https://openalex.org/I4210088115","display_name":"Ospedale Santa Chiara","ror":"https://ror.org/007x5wz81","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210088115"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Valeria Merz","raw_affiliation_strings":["Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy","Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Universit\u00e0 degli Studi di Verona, Verona, Italy"],"raw_orcid":"https://orcid.org/0000-0002-2120-1923","affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy","institution_ids":["https://openalex.org/I4210088115"]},{"raw_affiliation_string":"Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Universit\u00e0 degli Studi di Verona, Verona, Italy","institution_ids":["https://openalex.org/I119439378"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086805194","display_name":"Camilla Zecchetto","orcid":"https://orcid.org/0000-0002-1028-6431","observed_orcids":["https://orcid.org/0000-0002-1028-6431"]},"institutions":[{"id":"https://openalex.org/I119439378","display_name":"University of Verona","ror":"https://ror.org/039bp8j42","country_code":"IT","type":"education","lineage":["https://openalex.org/I119439378"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Camilla Zecchetto","raw_affiliation_strings":["Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Universit\u00e0 degli Studi di Verona, Verona, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Universit\u00e0 degli Studi di Verona, Verona, Italy","institution_ids":["https://openalex.org/I119439378"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100632841","display_name":"Yumin Zhao","orcid":"https://orcid.org/0000-0002-9365-1288","observed_orcids":["https://orcid.org/0000-0002-9365-1288"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yumin Zhao","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020397401","display_name":"Ivelina Gueorguieva","orcid":"https://orcid.org/0000-0001-5864-8924","observed_orcids":["https://orcid.org/0000-0001-5864-8924"]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ivelina Gueorguieva","raw_affiliation_strings":["Eli Lilly and Company, Erl Wood, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Erl Wood, UK","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110203091","display_name":"Michael Z. Man","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Man","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020504047","display_name":"Leena Gandhi","orcid":"https://orcid.org/0000-0002-2398-9179","observed_orcids":["https://orcid.org/0000-0002-2398-9179"]},"institutions":[{"id":"https://openalex.org/I4405272350","display_name":"Eli Lilly (Australia)","ror":"https://ror.org/041jqqq20","country_code":"AU","type":"company","lineage":["https://openalex.org/I4405272350"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Leena Gandhi","raw_affiliation_strings":["Eli Lilly and Company, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, New York, New York, USA","institution_ids":["https://openalex.org/I4405272350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041950187","display_name":"Shawn T. Estrem","orcid":"https://orcid.org/0009-0008-5173-6524","observed_orcids":["https://orcid.org/0009-0008-5173-6524"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shawn T Estrem","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006585898","display_name":"Karim Adnane Benhadji","orcid":"https://orcid.org/0000-0001-9883-6970","observed_orcids":["https://orcid.org/0000-0001-9883-6970"]},"institutions":[{"id":"https://openalex.org/I4405272350","display_name":"Eli Lilly (Australia)","ror":"https://ror.org/041jqqq20","country_code":"AU","type":"company","lineage":["https://openalex.org/I4405272350"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Karim A Benhadji","raw_affiliation_strings":["Eli Lilly and Company, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, New York, New York, USA","institution_ids":["https://openalex.org/I4405272350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056470372","display_name":"Mark C. Lanasa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark C Lanasa","raw_affiliation_strings":["AstraZeneca, Gaithersburg, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gaithersburg, Maryland, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021923655","display_name":"Emin Av\u015far","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405272350","display_name":"Eli Lilly (Australia)","ror":"https://ror.org/041jqqq20","country_code":"AU","type":"company","lineage":["https://openalex.org/I4405272350"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Emin Avsar","raw_affiliation_strings":["Eli Lilly and Company, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, New York, New York, USA","institution_ids":["https://openalex.org/I4405272350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112252143","display_name":"Susan C. Guba","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan C Guba","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048223620","display_name":"Rocio Garc\u00eda\u2010Carbonero","orcid":"https://orcid.org/0000-0002-3342-397X","observed_orcids":["https://orcid.org/0000-0002-3342-397X"]},"institutions":[{"id":"https://openalex.org/I121748325","display_name":"Universidad Complutense de Madrid","ror":"https://ror.org/02p0gd045","country_code":"ES","type":"education","lineage":["https://openalex.org/I121748325"]},{"id":"https://openalex.org/I4210101691","display_name":"Hospital Universitario 12 De Octubre","ror":"https://ror.org/00qyh5r35","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210101691","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210158561","display_name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","ror":"https://ror.org/04hya7017","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210158561"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Rocio Garcia-Carbonero","raw_affiliation_strings":["Hospital Universitario 12 de Octubre, Imas12, CNIO, UCM, CIBERONC, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario 12 de Octubre, Imas12, CNIO, UCM, CIBERONC, Madrid, Spain","institution_ids":["https://openalex.org/I121748325","https://openalex.org/I4210101691","https://openalex.org/I4210158561"]}]}],"institutions":[],"countries_distinct_count":7,"institutions_distinct_count":17,"corresponding_author_ids":["https://openalex.org/A5049680516"],"corresponding_institution_ids":["https://openalex.org/I119439378"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":13.1799,"has_fulltext":true,"cited_by_count":223,"citation_normalized_percentile":{"value":0.99430972,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"9","issue":"3","first_page":"e002068","last_page":"e002068"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11501","display_name":"TGF-\u03b2 signaling in diseases","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/galunisertib","display_name":"galunisertib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.9850000143051147},{"id":"https://openalex.org/keywords/tgf-beta-receptor-i-kinase-inhibitor","display_name":"TGF-beta receptor I kinase inhibitor","score":0.7960000038146973},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.8040000200271606},{"id":"https://openalex.org/keywords/metastatic-pancreatic-cancer","display_name":"metastatic pancreatic cancer","score":0.972000002861023},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7979999780654907},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.628000020980835},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9169999957084656},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7599999904632568},{"id":"https://openalex.org/keywords/tgf-beta-inhibition","display_name":"TGF-beta inhibition","score":0.6019999980926514}],"concepts":[{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.8899354934692383},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6561996936798096},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6062535047531128},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5656909942626953},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.5373671650886536},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5304864048957825},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.48150429129600525},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4422711431980133},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34715771675109863},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.338890939950943},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3261731266975403},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.23732072114944458},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.22712412476539612},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2073209285736084},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.20406976342201233},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077293","descriptor_name":"Receptor, Transforming Growth Factor-beta Type I","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D000077293","descriptor_name":"Receptor, Transforming Growth Factor-beta Type I","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000077982","descriptor_name":"Progression-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005060","descriptor_name":"Europe","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D056910","descriptor_name":"Republic of Korea","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1136/jitc-2020-002068","doi":"https://doi.org/10.1136/jitc-2020-002068","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-002068","pdf_url":"https://jitc.bmj.com/content/jitc/9/3/e002068.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},{"id":"pmid:33688022","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33688022","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for immunotherapy of cancer","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:pubmedcentral.nih.gov:7944986","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7944986/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Immunother Cancer","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:c175cf79b75445f3ae95a488c7252728","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/c175cf79b75445f3ae95a488c7252728","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)","raw_type":"article"},{"id":"pmh:oai:s-space.snu.ac.kr:10371/212771","doi":null,"is_oa":false,"landing_page_url":"https://hdl.handle.net/10371/212771","pdf_url":null,"source":{"id":"https://openalex.org/S4306401345","display_name":"Seoul National University Open Repository (Seoul National University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I139264467","host_organization_name":"Seoul National University","host_organization_lineage":["https://openalex.org/I139264467"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2020-002068","doi":"https://doi.org/10.1136/jitc-2020-002068","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-002068","pdf_url":"https://jitc.bmj.com/content/jitc/9/3/e002068.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal for ImmunoTherapy of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G2316550322","display_name":null,"funder_award_id":"23719","funder_id":"https://openalex.org/F4320323054","funder_display_name":"Associazione Italiana per la Ricerca sul Cancro"},{"id":"https://openalex.org/G2614405141","display_name":null,"funder_award_id":"12182","funder_id":"https://openalex.org/F4320323054","funder_display_name":"Associazione Italiana per la Ricerca sul Cancro"},{"id":"https://openalex.org/G2636645585","display_name":null,"funder_award_id":"\"5 x\u20021000\".","funder_id":"https://openalex.org/F4320321781","funder_display_name":"Ministero della Salute"},{"id":"https://openalex.org/G273746860","display_name":null,"funder_award_id":"GR-2016-02361134","funder_id":"https://openalex.org/F4320321781","funder_display_name":"Ministero della Salute"},{"id":"https://openalex.org/G4551861991","display_name":null,"funder_award_id":"23719","funder_id":"https://openalex.org/F4320321781","funder_display_name":"Ministero della Salute"},{"id":"https://openalex.org/G5000000976","display_name":null,"funder_award_id":"5X 1000","funder_id":"https://openalex.org/F4320323054","funder_display_name":"Associazione Italiana per la Ricerca sul Cancro"},{"id":"https://openalex.org/G5715214819","display_name":null,"funder_award_id":"2016-02361134","funder_id":"https://openalex.org/F4320321781","funder_display_name":"Ministero della Salute"},{"id":"https://openalex.org/G578721405","display_name":null,"funder_award_id":"GR-2016-02361134","funder_id":"https://openalex.org/F4320323054","funder_display_name":"Associazione Italiana per la Ricerca sul Cancro"},{"id":"https://openalex.org/G742029189","display_name":null,"funder_award_id":"2016-02361134","funder_id":"https://openalex.org/F4320323054","funder_display_name":"Associazione Italiana per la Ricerca sul Cancro"},{"id":"https://openalex.org/G9000856728","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA008748","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320321781","display_name":"Ministero della Salute","ror":"https://ror.org/00789fa95"},{"id":"https://openalex.org/F4320323054","display_name":"Associazione Italiana per la Ricerca sul Cancro","ror":"https://ror.org/02g2x7380"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3134477587.pdf","grobid_xml":"https://content.openalex.org/works/W3134477587.grobid-xml"},"referenced_works_count":48,"referenced_works":["https://openalex.org/W1700691315","https://openalex.org/W1705006587","https://openalex.org/W1970098795","https://openalex.org/W2044363258","https://openalex.org/W2045626840","https://openalex.org/W2062929087","https://openalex.org/W2066230562","https://openalex.org/W2102509488","https://openalex.org/W2143772132","https://openalex.org/W2285093314","https://openalex.org/W2299118744","https://openalex.org/W2331204012","https://openalex.org/W2344682920","https://openalex.org/W2467321712","https://openalex.org/W2529042945","https://openalex.org/W2599857500","https://openalex.org/W2609921003","https://openalex.org/W2773651127","https://openalex.org/W2775344839","https://openalex.org/W2779098860","https://openalex.org/W2785803176","https://openalex.org/W2788975052","https://openalex.org/W2804265459","https://openalex.org/W2807263356","https://openalex.org/W2887205254","https://openalex.org/W2890106882","https://openalex.org/W2896652675","https://openalex.org/W2898562712","https://openalex.org/W2898717093","https://openalex.org/W2899666133","https://openalex.org/W2906111025","https://openalex.org/W2917919815","https://openalex.org/W2919944461","https://openalex.org/W2920509406","https://openalex.org/W2921490723","https://openalex.org/W2931391344","https://openalex.org/W2940497723","https://openalex.org/W2945653463","https://openalex.org/W2946663348","https://openalex.org/W2953461318","https://openalex.org/W2959096163","https://openalex.org/W2971523106","https://openalex.org/W2971810940","https://openalex.org/W2988731068","https://openalex.org/W2999417355","https://openalex.org/W3003979238","https://openalex.org/W3006954450","https://openalex.org/W7045810429"],"related_works":["https://openalex.org/W2947504160","https://openalex.org/W2599807386","https://openalex.org/W2608573151","https://openalex.org/W2896652675","https://openalex.org/W2502709611","https://openalex.org/W2587864867","https://openalex.org/W2891989464","https://openalex.org/W2921490723","https://openalex.org/W2476049804","https://openalex.org/W4379282006"],"abstract_inverted_index":{"BACKGROUND:":[0],"We":[1],"assessed":[2],"the":[3,9,20],"safety,":[4],"efficacy,":[5],"and":[6,129,142,153,182],"pharmacokinetics":[7],"of":[8,55,214,221],"transforming":[10],"growth":[11],"factor":[12],"beta":[13],"(TGF\u03b2)":[14],"receptor":[15],"inhibitor":[16],"galunisertib":[17,56,83,113],"co-administered":[18,58,90,193],"with":[19,34,62,91,112,194],"anti-programmed":[21],"death-ligand":[22],"1":[23,70,115],"(PD-L1)":[24],"antibody":[25],"durvalumab":[26,65,92,195],"in":[27,208,210],"recurrent/refractory":[28],"metastatic":[29],"pancreatic":[30],"cancer":[31],"previously":[32],"treated":[33,111],"\u22642":[35],"systemic":[36],"regimens.":[37],"METHODS:":[38],"This":[39],"was":[40,96,137,176,199,203],"a":[41,49,226],"two-part,":[42],"single-arm,":[43],"multinational,":[44],"phase":[45,85],"Ib":[46],"study.":[47],"In":[48],"dose-finding":[50],"phase,":[51],"escalating":[52],"oral":[53],"doses":[54],"were":[57,106,131,145,167],"on":[59,68],"days":[60],"1-14":[61],"fixed-dose":[63],"intravenous":[64],"1500":[66,93,196],"mg":[67,94,98,188,197],"day":[69,192],"every":[71],"4":[72],"weeks":[73],"(Q4W),":[74],"followed":[75],"by":[76],"an":[77,211],"expansion":[78],"cohort":[79],"phase.":[80],"RESULTS:":[81],"The":[82],"recommended":[84],"II":[86],"dose":[87],"(RP2D)":[88],"when":[89],"Q4W":[95,198],"150":[97,187],"two":[99,189],"times":[100,190],"per":[101,191],"day.":[102],"No":[103],"dose-limiting":[104],"toxicities":[105],"recorded.":[107],"Among":[108],"32":[109],"patients":[110,209],"RP2D,":[114],"patient":[116],"had":[117,121,125],"partial":[118],"response,":[119],"7":[120],"stable":[122],"disease,":[123,128],"15":[124],"objective":[126],"progressive":[127],"9":[130],"not":[132],"evaluable.":[133],"Disease":[134],"control":[135],"rate":[136],"25.0%.":[138],"Median":[139],"overall":[140],"survival":[141,144],"progression-free":[143],"5.72":[146],"months":[147,155],"(95%":[148,156],"CI:":[149,157],"4.01":[150],"to":[151,159,169],"8.38)":[152],"1.87":[154],"1.58":[158],"3.09),":[160],"respectively.":[161],"Pharmacokinetic":[162],"profiles":[163],"for":[164,172,218],"combination":[165,207],"therapy":[166],"comparable":[168],"those":[170],"published":[171],"each":[173],"drug.":[174],"There":[175],"no":[177],"association":[178],"between":[179],"potential":[180],"biomarkers":[181,220],"treatment":[183,215],"outcomes.":[184],"CONCLUSION:":[185],"Galunisertib":[186],"tolerable.":[200],"Clinical":[201],"activity":[202],"limited.":[204],"Studying":[205],"this":[206],"earlier":[212],"line":[213],"or":[216],"selected":[217],"predictive":[219],"TGF\u03b2":[222],"inhibition":[223],"might":[224],"be":[225],"more":[227],"suitable":[228],"approach.":[229],"TRIAL":[230],"REGISTRATION":[231],"NUMBER:":[232],"ClinicalTrials.gov":[233],"identifier:":[234],"NCT02734160.":[235]},"counts_by_year":[{"year":2026,"cited_by_count":46},{"year":2025,"cited_by_count":44},{"year":2024,"cited_by_count":45},{"year":2023,"cited_by_count":36},{"year":2022,"cited_by_count":32},{"year":2021,"cited_by_count":18},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2021-03-15T00:00:00"}